From Moderna 
From the press release we learned that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Moderna (MRNA) investigational Zika vaccine (mRNA-1893) currently being evaluated in a Phase 1 study for the prevention of Zika virus infection in healthy adults.

This is good news for